Aktienanalyse zu MIRA Pharmaceuticals Inc (MIRA)MIRAMIRA Pharmaceuticals Inc

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Mira Pharmaceuticals Inc is a good buy right now due to its recent positive developments and potential for growth. The stock is currently priced at $0.57, significantly below its 52-week high of $1.69, indicating a potential upside of over 500%. Additionally, the analyst price target of $3.50 suggests a substantial upside from the current price. The RSI is at 50.69, indicating a neutral momentum which could shift positively. However, the company has reported consistent net losses, with the most recent EPS at -0.03, which remains a risk to consider.